GleamWall
中文EN

CCCC C4 Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%

Returns

ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$8.47M$6.64M$6.15M$11.02M$11.23M$6.46M$7.24M$5.18M
R&D expense$24.80M$24.47M$24.61M$24.98M$25.99M$26.20M$27.07M$32.51M
SG&A expense$8.26M$8.59M$9.33M$9.18M$8.92M$8.77M$9.33M$10.37M
Operating income-$24.60M-$26.42M-$27.79M-$23.14M-$34.41M-$28.50M-$29.16M-$37.71M
Pretax income———-$20.36M-$32.17M-$26.02M-$26.32M-$34.44M
Income tax$0$0$0$121,000$0$0$0$131,000
Net income-$21.84M-$23.64M-$25.13M-$20.49M-$32.17M-$26.02M-$26.32M-$34.57M
EBITDA-$24.28M-$26.09M-$27.38M-$22.72M-$34.03M-$28.09M-$28.71M-$37.23M
EPS (basic)-0.16-0.18-0.20—-0.44-0.37-0.37—
EPS (diluted)-0.16-0.18-0.20—-0.44-0.37-0.37—
Weighted avg. shares (diluted)136.08M130.70M126.07M—72.56M71.01M70.83M—
Balance sheet
Cash & equivalents$32.42M$78.61M$61.27M$74.60M$58.81M$78.16M$51.29M$58.94M
Receivables$1.41M$1.33M$2.88M$2.40M$6.54M$2.16M$8.03M$3.10M
Current assets$214.50M$262.90M$245.37M$258.11M$206.86M$224.73M$232.53M$257.77M
PP&E, net$3.83M$4.15M$4.49M$4.74M$5.13M$5.54M$5.48M$5.84M
Total assets$331.80M$359.40M$328.86M$359.07M$265.49M$296.53M$319.52M$349.60M
Current liabilities$41.46M$48.25M$27.25M$33.03M$35.95M$44.46M$40.82M$45.18M
Total liabilities$103.63M$112.14M$94.61M$102.49M$111.08M$122.46M$124.38M$133.62M
Shareholders' equity$228.17M$247.26M$234.25M$256.59M$154.41M$174.06M$195.14M$215.99M
Shares outstanding131.31M122.91M104.04M96.91M74.17M71.01M70.99M70.63M
Cash flow statement
Operating cash flow-$25.97M-$1.57M-$29.94M-$22.14M-$31.21M-$12.06M-$33.28M-$17.93M
Capital expenditure$0$37,000$64,000$11,000$411,000$185,000$0-$4,000
Free cash flow-$25.97M-$1.61M-$30.01M-$22.16M-$31.62M-$12.24M-$33.28M-$17.93M
Investing cash flow-$20.58M-$14.81M$16.15M-$80.73M$4.09M$38.92M$29.12M$13.67M
Financing cash flow$359,000$33.73M$462,000$118.67M$7.77M$0-$46,000$112,000
Depreciation & amortization$320,000$336,000$404,000$428,000$384,000$416,000$456,000$480,000
Stock-based compensation$2.98M$3.04M$2.67M$4.01M$4.59M$4.99M$5.51M$8.23M
Share buybacks$39,000$0$200,000$14,000$24,000$0$155,000$0

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.